Denosumab for the treatment of osteoporosis
Denosumab for the treatment of osteoporosis
复制标题
DOI：
10.1016/j.afos.2017.01.002
复制
发表时间：
2017-02
影响因子：
2
通讯作者：
M. McClung
中科院分区：
文献类型：
--
作者：
M. McClung
Denosumab是RANK配体的特异性抑制剂，是治疗绝经后骨质疏松症和相关疾病的新疗法。一项广泛的临床开发计划评估了Denosumab的临床有效性和安全性，对数千名患者进行了长达10年的跟踪调查。结合六年多的上市后经验，这些研究提供了很大的信心，即denosumab对包括亚洲人在内的骨折高危患者来说是一种方便和适当的治疗方法。这篇综述将总结迪诺单抗的临床发展和自2010年批准临床使用以来的经验教训。
Denosumab, a specific inhibitor of RANK ligand, is a novel therapy for postmenopausal osteoporosis and related disorders. An extensive clinical development program has evaluated the clinical efficacy and safety of denosumab with several thousand patients being followed for up to 10 years. Combined with more than six years of postmarketing experience, these studies provide substantial confidence that denosumab is a convenient and appropriate treatment for patients, including Asians, at high risk for fracture. This review will summarize the clinical development of denosumab and lessons learned since its approval for clinical use in 2010.